Scienture (SCNX) announced the start of commercial sales and fulfillment of the first customer orders for Arbli Oral Suspension, 10 mg/mL, marking an important milestone in the Company’s growth as it begins to bring this differentiated product to market. Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. As part of its commercial campaign, Scienture is executing targeted outreach for Arbli to healthcare professionals and has finalized PBM-Led GPO agreements for expanded commercial coverage and formulary access.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCNX:
- Scienture Holdings Faces Nasdaq Non-Compliance Notice
- Scienture Holdings Completes Note Purchase Agreement
- Scienture’s Arbli is commercially available through wholesalers nationwide
- Scienture announces repayment, conversion of outstanding debentures
- Scienture Holdings Amends Bylaws for Quorum Change